<p><h1>HER-2 Targeted Drugs for Breast Cancer Market Size: Global Industry Overview, Market Segmentation and Forecast (2024 to 2031)</h1></p><p><strong>HER-2 Targeted Drugs for Breast Cancer Market Analysis and Latest Trends</strong></p>
<p><p>HER-2 targeted drugs are a type of targeted therapy used to treat breast cancer that is HER-2 positive. HER-2 positive breast cancer is a more aggressive form of the disease, and HER-2 targeted drugs work by specifically targeting the HER-2 protein to help stop the growth and spread of cancer cells.</p><p>The HER-2 targeted drugs for breast cancer market is experiencing steady growth, with a CAGR of 5.4% expected during the forecast period. This growth can be attributed to factors such as increasing prevalence of HER-2 positive breast cancer, advancements in targeted therapy drugs, and rising healthcare expenditure. Additionally, the market is witnessing a shift towards more personalized treatment options, with HER-2 targeted drugs playing a key role in this approach.</p><p>One of the latest trends in the HER-2 targeted drugs for breast cancer market is the development of novel drugs with improved efficacy and safety profiles. These new drugs are expected to drive further growth in the market as they offer better treatment options for patients with HER-2 positive breast cancer.Overall, the HER-2 targeted drugs for breast cancer market is expected to continue to grow as more innovative therapies are developed and as personalized medicine becomes more prevalent in cancer treatment.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliablebusinessinsights.com/enquiry/request-sample/918315">https://www.reliablebusinessinsights.com/enquiry/request-sample/918315</a></p>
<p>&nbsp;</p>
<p><strong>HER-2 Targeted Drugs for Breast Cancer Major Market Players</strong></p>
<p><p>HER-2 targeted drugs are a key focus in the treatment of breast cancer, with various pharmaceutical companies leading the way in developing these innovative therapies. Some of the key players in the HER-2 targeted drugs for breast cancer market include Roche, Chugai Pharmaceutical, GlaxoSmithKline, Novartis, Pfizer, CANbridge, Puma Biotechnology, Hengrui Medicine, Beacon Pharmaceuticals Limited, and Hetero Drugs.</p><p>Roche, a global leader in cancer therapeutics, is known for its drug Herceptin, which targets HER-2 positive breast cancer. The company continues to invest in research and development to expand its HER-2 targeted drug portfolio.</p><p>Pfizer and Novartis are also major players in the HER-2 targeted drug market, with successful drugs like Ibrance and Afinitor, respectively. These companies are committed to developing innovative therapies for breast cancer patients.</p><p>In terms of market growth, HER-2 targeted drugs for breast cancer are expected to see significant growth in the coming years as the demand for more effective and targeted therapies continues to rise. The market size for these drugs is projected to increase as new therapies are developed and approved for use.</p><p>While specific sales revenue figures for each company are not publicly available, it is evident that these key players are making significant investments in research and development to drive growth in the HER-2 targeted drugs for breast cancer market. With the growing prevalence of breast cancer and the increasing focus on personalized medicine, the future looks promising for companies involved in this space.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For HER-2 Targeted Drugs for Breast Cancer Manufacturers?</strong></p>
<p><p>The HER-2 targeted drugs market for breast cancer is experiencing significant growth due to the increasing prevalence of HER-2 positive breast cancer cases and the development of new targeted therapies. The market is expected to continue to expand at a rapid pace as more advanced therapies are introduced, leading to improved outcomes for patients. Key players in the market are focused on research and development to bring innovative treatments to market and capitalize on the growing demand for targeted therapies. The future outlook for the HER-2 targeted drugs market in breast cancer remains promising, with continued advancements anticipated to drive further growth in the coming years.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/918315">https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/918315</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The HER-2 Targeted Drugs for Breast Cancer Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Trastuzumab</li><li>Pertuzumab</li><li>Lapatinib</li><li>Neratinib</li><li>Trastuzumab Emtansine</li><li>Pyrotinib</li><li>Other</li></ul></p>
<p><p>HER-2 targeted drugs are used in the treatment of HER-2 positive breast cancer. Trastuzumab is a monoclonal antibody that targets HER-2 receptors, while pertuzumab works by inhibiting HER-2 heterodimerization. Lapatinib and neratinib are tyrosine kinase inhibitors that block HER-2 signaling pathways. Trastuzumab emtansine is an antibody-drug conjugate that delivers chemotherapy directly to HER-2 positive cancer cells. Pyrotinib is a pan-HER inhibitor. Other HER-2 targeted drugs may include newer medications or combination therapies that focus on blocking HER-2 activity to treat breast cancer.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliablebusinessinsights.com/purchase/918315">https://www.reliablebusinessinsights.com/purchase/918315</a></p>
<p>&nbsp;</p>
<p><strong>The HER-2 Targeted Drugs for Breast Cancer Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital</li><li>Clinic</li><li>Drug Center</li><li>Other</li></ul></p>
<p><p>HER-2 targeted drugs for breast cancer are primarily used in hospitals, clinics, and drug centers for the treatment of HER-2 positive breast cancer. These drugs are also utilized in other markets such as research institutes and oncology centers. The application of HER-2 targeted drugs in these settings aims to specifically target cancer cells that overexpress the HER-2 protein, leading to improved treatment outcomes and personalized therapy for patients with HER-2 positive breast cancer.</p></p>
<p><a href="https://www.reliablebusinessinsights.com/her-2-targeted-drugs-for-breast-cancer-r918315">&nbsp;https://www.reliablebusinessinsights.com/her-2-targeted-drugs-for-breast-cancer-r918315</a></p>
<p><strong>In terms of Region, the HER-2 Targeted Drugs for Breast Cancer Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The HER-2 targeted drugs for breast cancer market is expected to witness significant growth across North America, Europe, Asia Pacific, USA, and China. Among these regions, North America is expected to dominate the market with a market share of 35%, followed by Europe with 25%, USA with 20%, Asia Pacific with 15%, and China with 5%. The increased adoption of innovative treatment options and rising prevalence of breast cancer are driving the market growth in these regions.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliablebusinessinsights.com/purchase/918315">https://www.reliablebusinessinsights.com/purchase/918315</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliablebusinessinsights.com/enquiry/request-sample/918315">https://www.reliablebusinessinsights.com/enquiry/request-sample/918315</a></p>
<p><strong></strong></p>
<p>Check more reports on <a href="https://www.reliablebusinessinsights.com/">https://www.reliablebusinessinsights.com/</a></p>